Novocol Pharma, headquartered in Cambridge, Ontario, Canada, is a leading provider of bespoke pharmaceutical development and manufacturing services with over 40 years of industry expertise. As a proud member of the Septodont Group, the company partners with biopharmaceutical and pharmaceutical innovators — from emerging biotech start-ups to top 5 global pharma firms — offering tailored CDMO capabilities that span early-stage formulation through to commercial production and combination product assembly. Novocol Pharma is recognised for its personalised, flexible approach, quality-focused execution and strategic integration of drug product manufacturing with device assembly to streamline customers’ supply chains and accelerate time to market.

Key products and services

• Aseptic fill-finish manufacturing – Clinical and commercial sterile injectable fill-finish for cartridges, vials and syringes.
• Contract development and analytical services – Formulation development, process optimisation, analytical method development and stability testing.
• Drug delivery design and device innovation – Collaboration with Duoject Medical Systems to design and develop advanced drug-delivery devices.
• Combination product assembly – End-to-end assembly of drug products with delivery systems to reduce customer supply chain complexity.
• Technology transfer and scale-up – Support for transferring and scaling processes from development through to high-volume commercial manufacturing.

With a robust global footprint and regulatory approvals across major markets, Novocol Pharma continues to expand its fill-finish and development capabilities, reinforcing its position as a trusted CDMO partner. Its long heritage in sterile injectable manufacturing, complemented by strategic partnerships — such as recent collaborations to support mRNA vaccine fill-finish — underscores the company’s commitment to quality, innovation and responsive service delivery in the evolving pharmaceutical landscape.